Warnex has announced that its Bioanalytical Services division has acquired two TSQ Vantage mass spectrometers from Thermo Fisher Scientific.
'The increased sensitivity of this new generation of systems will allow us to detect compounds at very low quantitation levels with great precision,' said Mark Busgang, president and chief executive officer of Warnex.
The TSQ Vantage system delivers increased sensitivity and does not produce a commensurate increase in noise.
It offers high signal-to-noise performance, providing better reproducibility and precision in the quantitative analysis of small molecules, biomolecules and peptides, said Thermo Fisher.
Warnex Bioanalytical offers a range of services to the pharmaceutical and biotechnology industries, specialising in bioavailability and bioequivalence studies.
A scientific team of specialists will support companies in their drug development programmes by carrying out analyses generated throughout the program, beginning with pre-clinical studies and proceeding with evaluation of the drug in human clinical trials.
Support to the generic drug industry is provided by analysing physiological fluid samples obtained from clinical studies in humans to determine whether the new formulations are bioequivalent to the marketed product.
